Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise
Biogen (NASDAQ: BIIB) grew earnings faster than revenue in the third quarter, which is what investors should be looking for from any mature company in their portfolio. Nevertheless, shares went down yesterday after reporting earnings because top-line revenue growth is still indicative of the biotech's future; companies can only cut costs for so long.
Metric
Q3 2017
Source: Fool.com
Biogen Inc. Stock
€185.20
-0.050%
With 51 Buy predictions and 2 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 284 € shows a very positive potential of 53.35% compared to the current price of 185.2 € for Biogen Inc..